Home / Business / Mobile bank Chime picks up credit score improvement service Pinch in all-stock deal

Mobile bank Chime picks up credit score improvement service Pinch in all-stock deal

Chime, the no-fees mobile bank valued at $500 million as of its last round, has put some of its funds to use with its first acquisition. The deal is for Pinch, a startup that was focused on helping millennials and other young adults build better credit. It was best known for a service called PinchRent, which allowed users to increase their credit scores over time by reporting on-time rent payments to credit bureaus.

Millennials can sometimes struggle to improve their credit, or are uneducated about what their credit scores mean, studies have shown. And like any younger demographic, they may also be afflicted with shorter credit histories, which impacts those scores, too.

Many in this age group have said that their low credit scores are holding them back, and millennials prefer debit to credit, Visa has reported.

Pinch’s focus was to provide a different way for its users to increase their scores, rather than simply using credit cards or making loan payments on time.

It did this by aggregating the information on rent payments and submitting that to the credit bureaus. (The bureaus can take rental information, but they don’t work with individual landlords. That’s where Pinch came in.)

Since its founding in 2016, more than 80% of people on its service increased their scores from 10 to 100 points.

The startup was preparing to announce a $1.8 million seed round of funding from Homebrew and Collaborative ahead of its acquisition.

Pinch had only been in beta testing prior to joining Chime, and was also planning to do a full public launch. Instead, it shut down its service by alerting users via email that its last day of business would be June 27, 2018.

At the time of the service’s closure, it was in talks with Chime. But the deal itself only closed this Tuesday, we understand.

Chime declined to share the deal terms, but noted it’s an all-stock transaction and investors were happy.

The acquisition includes Pinch’s core team (5-10 people, depending on how the offers play out) plus founders Maia Bittner and Michael Ducker, who will now help the mobile bank launch credit and lending products over the next six months.

Bittner previously co-founded subscription startup Rocksbox, and worked as a Sequoia Capital scout. Ducker, meanwhile, hailed from Microsoft and Twitter before starting Pinch.

Chime, whose user base is 90% millennials, may or may not relaunch Pinch’s rent-paying service, but it will be soon moving into credit.

“I think, particularly, post the 2008 crisis, there’s been just a general distrust of big banks. But also, people have seen how the amount of credit [they have] can create challenges in their life,” says Chime CEO Chris Britt, discussing the struggles its users face in terms of building their credit.

“And younger consumers are so saddled with with student loan debt that the last thing they want to do is get more debt on a credit card,” he adds, explaining why young people turn to debit cards.

He says Chime’s goal now is to helping serve this group’s needs around credit with a set of millennial-focused products.

“The reality is the typical debit card and checking account do nothing to build your credit score. So as we think about the future set of products that we want to roll out, we’re very focused on helping our members with that part of their life,” he adds.

Chime is now one of several millennial-focused mobile banks on the market, which do away with traditional banking fees as well as brick-and-mortar location. Others like Simple and Stash are also available, but Chime has raised over $110 million, making it the largest in terms of funding.

The company today also shared new numbers – it says it has over 1.7 million bank accounts on its platform, and is opening more than 150,000 accounts per month – in line with Wells Fargo. It expects to surpass 2 million bank accounts and $10 billion in total transaction volume by year-end.

Further down the road, Chime may venture into investing, but not until its user base is ready.

“So we’re very deliberate in how we think about helping our members along their financial journey. We start with the checking account, we make sure you’re paying all your bills, then we make sure you have a savings account balance – because you should have a savings account balance before you start day trading,” Britt says.

“It’s sort of irresponsible to be encouraging day trading if you don’t have the financial means…I think investment accounts and retirement accounts come first,” he notes.

Check Also

Ezra raises $4M to diagnose cancer with MRIs, not painful biopsies

1 in 41 men will die of prostate cancer. But sticking a needle through your rectum into your prostate to screen for cancer brings along a ton of bacteria and terrible side effects like pain, infection, urinary trouble, and even erectile dysfunction. It turns out you can detect cancer with Magnetic Resonance Imaging…it’s just prohibitively expensive to do one-off MRIs and have radiologists analyze the scans. But by buying MRI slots in bulk and using artificial intelligence to scan them, a new medtech startup called Ezra wants to replace blood tests and biopsies with MRIs as the new standard of care. Today, Ezra launches v1 of its MRI prostate cancer screening subscription service in New York City. For $999 per year, patients get one MRI, access to medical staff and educational guides, and on-going support if the test finds they have cancer. For now, human radiologists still analyze the scans. However, Ezra is working to get FDA approval next year for its AI analysis that’s was initially found to be 90 percent as accurate as medical experts, and could turn Ezra into a lucrative and scalable medtech company. Comparing Radiologist and AI detection of cancer in MRI scans “One of the biggest problems in cancer is that there’s no accurate, fast, painless, way to scan for cancer anywhere in the body” says Ezra co-founder and CEO Emi Gal. He hopes that eventually, Ezra could offer full-body MRIs that make screening for all types of cancer easier to stomach so more cases can be caught early and more patients can survive. To build out its team and market to potential patients at risk for prostate cancer, Ezra is also announcing it’s raised a $4 million seed round led by Accomplice, the health-focused VC that funded PillPack before it was acquired by Amazon for nearly $1 billion. The firm was attracted by Ezra’s 50 percent gross margin on subscriptions that could get even higher at lower subscription prices once its AI is approved. “We’re not losing money every sale” Gal tells me. And while $999 might sound steep, he says a prostate MRI will cost you $1500 if you book it yourself. With 30 million men in the US alone at risk of prostate cancer, there’s urgent need for Ezra to fulfill its mission of “making MRI-based cancer screening affordable to everyone.” Ezra’s Super Hero Origin Gal has one of those startup founder super hero origin stories that gives him the grit necessary to see the problem through. “I developed hundreds of moles as a child that put me at very high risk of melanoma. Every year I’ve had to check for abnormalities and do a couple of biopsies” he candidly revealed. “I’ve been acutely aware of the importance of cancer screening since a young age.” Ezra co-founder and CeO Emi Gal After studying computer science and applied math in his home country of Romania, he built an adtech company at age 20 and sold it at 30. While working with terminally ill cancer patient charity Hospices Of Hope, he seized on the need for better cancer screenings and began his research about different methods. “The more scientists I spoke to, the more convinced I became to build a new screening modality” he recalls. Typically, prostate cancer screenings involve a blood test for prostate-specific antigen, with an needle-through-the-rectum biopsy done if PSA levels are elevated. But PSA levels can be inaccurate, triggering painful and unnecessary biopsies. Gal discovered a recent study by a leading urologist that looked at 500 patients with some diagnosed the traditional way, and some with an MRI that when cancer is detected is then used to guide a biopsy. The latter method identified 18 percent more cases of cancer while reducing unnecessary biopsies and the associated side effects by 27 percent, the study found. MRIs could work. So Ezra conducted its own investigation to see if AI could perform as well as a radiologist. It had three experts mark up a data set from the National Institute Of Health and trained its AI on the data set through the work of Gal’s co-founder Diego Canto, a PhD in deep learning applied to MRI. They found the AI was 90 accurate at agreeing with the experts on a new data set. Now an FDA regulatory expert on the team is trying to get the AI approved to assist radiologists to lower Ezra’s labor costs. Magnetic Resonance Innovation Rather than wait around, Ezra has partnered with the leading MRI facility network RadNet. It buys MRI time slots in bulk for a cheaper rate, starting with a location in Lenox Hill, Manhattan. Next year it will expand to more RadNet locations beyond New York City. If the AI gets approval, there’ll still be human medical experts involved. The AI eliminates the grunt work of doing measurements and annotating MRI scans so the human can focus on just making the cancer/not cancer call. And if the diagnosis sadly is positive, “What we don’t want to do is just drop a report on people that says ‘you likely have cancer’. We want to help with the treatment process and recommend the best urologists” Gal tells me. A study found AI to agree with medical experts on prostate cancer detection 90 percent of the time The combination of hard technology and the booming direct-to-consumer industry drew the $4 million round that also includes Founders Future, Credo Ventures, Seedcamp, Esther Dyson and a number of startup founders and angel investors like SoundCloud co-founder Alex Ljung. They see Ezra as differentiated from expensive overall health screening services like the $25,000 Human Longevity Inc. “Ezra’s uniqueness stands as much in the company’s investigational AI technology as it does in its innovative consumer-centric cancer screening model” says John Crues, M.D. RadNet’s Medical Director. But the biggest threat to Ezra is insurance. If it can’t convince insurers that MRIs that are expensive up front but could be more accurate with fewer complications are more capital efficient long-term than the biopsy status quo, it may have a very tough time getting people to pay $1000 out of pocket. It will also have to find the right balance of margins and affordability that insurers will tolerate. “We want to focus on building a data set that proves [MRIs] are more accurate, less painful, and faster than that the standard of care” Gal concludes. If it can institute MRIs as the new standard for prostate screenings, Ezra will be on its way to offering a single painless test that could spot cancer early enough that it can be beaten. Cancer will kill 9.6 million people this year. It doesn’t have to be that way.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Disclaimer: Trading in bitcoins or other digital currencies carries a high level of risk and can result in the total loss of the invested capital. theonlinetech.org does not provide investment advice, but only reflects its own opinion. Please ensure that if you trade or invest in bitcoins or other digital currencies (for example, investing in cloud mining services) you fully understand the risks involved! Please also note that some external links are affiliate links.